Patrick Forde: Adjuvant durvalumab for resected lung cancer

Patrick Forde shared a post on X:

“BR31 by Dr. Glen Goss, a herculean academic effort examining adjuvant durvalumab for resected lung cancer sadly negative, pushes the narrative even more toward neoadj/periop, the results by PD-L1 suggest this was a study destined to be negative.”

Source: Patrick Forde/X

Dr. Patrick Forde is a Professor at The Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center. He also serves as the Director of the Thoracic Oncology Research Program at the Johns Hopkins University School of Medicine. Dr. Forde’s research focuses on the role of immunotherapy in treating mesothelioma and lung cancer, and his work has led to the initiation of several ongoing phase 3 clinical trials.